Thermo Fisher Scientific Inc. (TMO)
NYSE • Healthcare
October 2, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Thermo Fisher Scientific Inc. keeps $14 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 21
in 18 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Thermo Fisher Scientific beat on both revenue and adjusted EPS in the second fiscal quarter of 2026, based on preliminary results reported July 23. Revenue rose about 11% to about $12.0 billion, beating the roughly $11.7 billion estimate by about 3%, while gross margin held near 41% and operating margin around 17%. Adjusted EPS of $6.03 topped the $5.72 consensus by about 5%, and net income climbed 7% to about $1.7 billion from $1.62 billion a year earlier. The Laboratory Products and Biopharma Services segment remained the largest at about $6.0 billion, up 7%, and North America was the biggest region at about $5.7 billion, up 4%. Operating cash flow was about $2.1 billion, and the company repurchased about $1.0 billion of stock while paying about $175 million in dividends. Next-period consensus calls for EPS of $6.37 on revenue of $11.96 billion.
Next report — what to expect
Thermo Fisher Scientific (TMO) reports next on October 28, 2026. Wall Street is looking for consensus EPS of $6.40 on consensus revenue of $11.95 billion. As trailing context, revenue rose +10.5% year over year last quarter. TMO has beaten EPS in 8 of 8 most recent quarters.
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. develops and sells tools and services for research, diagnostics, and biopharma production, operating in the healthcare and Medical - Diagnostics & Research space. On the NYSE under TMO, it generated $44.6 billion of revenue in FY2025.
Today's Snapshot
TMO ended the day slightly higher at 655.00, in line with a flat sector. Trading was lighter than usual, with volume about two-thirds of its usual level. Thermo Fisher Scientific launched Precure LLC, a disease-detection venture, with Mayo Clinic, a medical center.
Trading Volume
Below 10d avg (2.1M)
1.3M
vs S&P 500 Today
Moderate Underperformance
-0.40%
Updated: October 2, 2026 at 20:07 UTC
TMO Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$566.02 - $661.73Buy
- RSI (14)56.59Neutral
- Stochastic %K (14, 3, 3)69.24Neutral
- MACD Level (12, 26)16.40Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.